Skip to main content
Clinical Trials/CTRI/2023/04/051458
CTRI/2023/04/051458
Recruiting
Phase 2

Short course radiotherapy based total neoadjuvent therapy with or without chlorophyllin - SCOTCH study

Tata Memorial Hospital0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: C20- Malignant neoplasm of rectum
Sponsor
Tata Memorial Hospital
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Age \> 18 years.
  • 2\.Histologically confirmed diagnosis of adenocarcinoma of the rectum.
  • 3\.Clinical Stage II/III (T2\-3, 4b: adherent to prostate, SV or post vagina but not grossly invading, N0\-2\) based on MRI.
  • 4\.Non\-circumferential tumours with craniocaudal length \<7 cm
  • 5\.The tumours of the lower rectum, or starting up to 7 cm from the anal verge.
  • 6\.No evidence of distant metastases on CT Chest and Abdomen.
  • 7\.No prior pelvic radiation therapy
  • 8\.No prior chemotherapy or surgery for rectal cancer
  • 9\.ECOG Performance status 0\-2
  • 10\.Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.

Exclusion Criteria

  • \-Signet or mucinous histology cancer of rectum
  • \-Recurrent rectal cancer or previous pelvic radiotherapy
  • \-Primary unresectable rectal cancer.
  • \-Creatinine level greater than 1\.5 times the upper limit of normal.
  • \-Patients who are unable to undergo an MRI.
  • \-Patients with a history of any arterial thrombotic event within the past 6 months. This includes angina stable or unstable, MI, TIA, or CVA.
  • \-Ulcerative colitis or any other histologically confirmed inflammatory bowel disease.
  • \-Patients with a history of venous thrombotic episodes such as deep venous thrombosis, and pulmonary embolism occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, patients who are anticoagulated for a trial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
  • \-Patients with any other concurrent medical or psychiatric condition or disease which, in the investigators judgment would make them inappropriate candidates for entry into this study.
  • \-Poor reliability for follow up.

Outcomes

Primary Outcomes

Not specified

Similar Trials